01—Abstract
Summary
Summary of the 8-K filed May 21, 2024. Cited figures are marked; the original filing is the authoritative source.
On May 21, 2024, Curtiss-Wright (NYSE: CW) hosted its 2024 Investor Day in New York City, furnishing the investor presentation and press release under Item 7.01 (Regulation FD).
The event was used to review the company's "Pivot to Growth" strategy and to introduce new three-year financial targets covering 2024–2026, with 2023 as the base year. Management reaffirmed full-year 2024 guidance of 5%–7% sales growth, 5%–8% operating income growth, an operating margin of 17.4%–17.6%, EPS growth of 8%–11%, and free cash flow of $415a–$435 million. The filing does not contain new financial statements; Items 9.01(a) and (b) are marked not applicable.
The headline targets are a total organic revenue CAGR above 5%, operating income growth exceeding revenue growth, top-quartile margin performance relative to the proxy peer group, an EPS CAGR above 10%, and free cash flow conversion above 105% on more normalized capital expenditures (returning CapEx to about 2% of sales). Management cited a track record that supports these goals: from 2021 to 2023 the company's adjusted EPS grew at a 12.5% CAGR, organic sales at a 4.7% CAGR, and average FCF conversion was 108%. The company also reported a backlog above $3 billionb as of March 31, 2024, and a Q1 2024 book-to-bill of 1.26x.
The key upside not included in the targets is commercial nuclear, particularly the AP1000 reactor. Management stated that the targets exclude any AP1000 order within the window, and it laid out an "art of the possible" scenario in which annual commercial nuclear revenue doubles by the end of 2028 from a 2023 base of $287 millionc. Investors should note that the outlook is forward-looking, subject to the risks listed in the filing, and that management has disclaimed any duty to update these statements.
02—Key points
Key Highlights
- New 3-year targets (2024–2026): organic revenue CAGR above 5%, operating income growth above revenue growth, top-quartile margin performance, EPS CAGR above 10%, and FCF conversion above 105%.
- 2024 guidance reaffirmed: sales growth of 5%–7%, operating income growth of 5%–8%, operating margin of 17.4%–17.6%, EPS growth of 8%–11%, and free cash flow of $415–$435 million.
- Track record cited: 2021–2023 adjusted EPS CAGR of 12.5%, organic sales CAGR of 4.7%, operating margin up 110 bps since 2020, and average FCF conversion of 108%.
- Record backlog above $3 billion as of March 31, 2024, with a Q1 2024 book-to-bill of 1.26x.
- Commercial nuclear upside optionality: the targets exclude any AP1000 order, and management sees a path to doubling annual commercial nuclear revenue (base of $287M in 2023) by the end of 2028, with $1.5B+ in potential European AP1000 opportunities.
- Capital allocation: ~$1.2B of operating cash flow generated over 2021–2023, with ~$450M in buybacks and ~$88M in dividends, and a balance sheet with 1.1x adjusted net debt/EBITDA and a $750M undrawn revolver.
- Defense and aerospace growth drivers include Columbia-class submarine production, the SSN(X) program, electromechanical actuation, and Foreign Military Sales, which together underpin the organic growth assumptions.
03—Questions
Frequently Asked Questions
What are Curtiss-Wright's new long-term financial targets for 2024–2026?
Curtiss-Wright introduced a total organic revenue CAGR above 5%, operating income growth greater than revenue growth (implying margin expansion), top-quartile margin performance versus its proxy peer group, an EPS CAGR above 10%, and free cash flow conversion above 105% on more normalized capital expenditures. The targets use 2023 as the base year and exclude any AP1000 reactor order.
Did the company change its 2024 guidance at Investor Day?
No. Management reaffirmed its 2024 outlook as of May 1, 2024: sales growth of 5%–7%, operating income growth of 5%–8%, operating margin of 17.4%–17.6%, EPS growth of 8%–11%, and free cash flow of $415–$435 million.
What is the commercial nuclear opportunity that is not included in the targets?
The targets exclude a potential AP1000 reactor order. Management estimated $1.5B+ in long-term AP1000 opportunity in Europe, assuming 20–25 Gen III+ plants are built and Westinghouse wins 50% of them. Management also described an upside scenario in which commercial nuclear revenue doubles by the end of 2028, with the base being $287M in 2023 sales. These are management projections, not guidance.
Is this 8-K reporting new financial results?
No. The filing furnishes the Investor Day press release and presentation under Item 7.01 (Regulation FD). It contains no new financial statements, and Items 9.01(a) and (b) are not applicable. The information is not deemed filed under Section 18 of the Exchange Act.
What are the main risks to achieving these targets?
The filing's forward-looking statements cite reduced anticipated orders, economic downturns, changes in competitive dynamics or customer requirements, changes in government spending, inability to perform customer contracts at anticipated costs, and other industry-wide factors. Management also flagged macro headwinds, the need to keep investing in R&D, talent, and systems, and the execution risk of acquisitions. Full details are in the company's 10-K and subsequent SEC filings.
04—Continue